B-CELL MALIGNANCIES
Clinical trials for B-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug called AZD5492 in people with B-cell blood cancers that have come back or not responded to at least two prior treatments. The drug is designed to help the body's immune T cells attack cancer cells. The main goals are to check if the drug is s…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called SHB-04-CD22 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cance…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug duo aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether adding emavusertib to an approved BTK inhibitor (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia or other B-cell cancers. About 108 participants will receive the combination to see if it leads to undetectable cancer cells o…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses a mix of specially engineered immune cells designed to attack cancer cells in multiple ways. The goal is to see if this combinat…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New pill for blood cancers enters first human tests
Disease control Recruiting nowThis early-phase study tests an experimental drug called ABBV-525 in about 150 adults with B-cell blood cancers (like certain lymphomas and leukemias). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants take the drug by mouth …
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR19 for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to better find and attack cancer cells. The goal is to see if it is safe and ef…
Matched conditions: B-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC